Clinical Trial Update: Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612 [Phase 2]

View source ↗

Summary

A Phase 2 study in children assessing non-inferiority and antibody persistence up to five years for GSK's meningococcal vaccine 134612; results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• GSK Bio Meningococcal Vaccine 134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2018-06-04